UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) February 8, 2010
NOVAVAX, INC.
(Exact name of Registrant as specified in its charter)
|
|
|
|
|
Delaware
(State or other jurisdiction of incorporation or
organization)
|
|
0-26770
(Commission File Number)
|
|
22-2816046
(I.R.S. Employer Identification No.) |
|
|
|
9920 Belward Campus Drive
Rockville, Maryland
(Address of principal executive offices)
|
|
20850
(Zip Code) |
Registrants telephone number, including area code: (240) 268-2000
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
On February 1, 2010, James Robinson, the former Vice President, Technical and Quality Operations of
Novavax, Inc. (the Company) executed a General Release of Claims and Restrictive Covenants
Agreement (the Release). The revocation period for the Release expired on February 8, 2010, at
which time the Release became irrevocable. In exchange for Mr. Robinsons release of the Company
of general claims and agreement not to compete with, or solicit from, the Company for a period of
six months, the Company will pay Mr. Robinson a lump sum severance amount of $95,000.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused
this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
Novavax, Inc.
(Registrant)
|
|
February 9, 2010 |
By: |
/s/ Frederick W. Driscoll
|
|
|
|
Name: |
Frederick W. Driscoll |
|
|
|
Title: |
Vice President, Chief Financial Officer and
Treasurer |
|
|
3